Wearable diagnostics are poised to transform subjective, episodic measures of disease progression to quantified, continuous data streams, according to some industry experts.

FreeStyle Libre CGMs, a breakthrough in diabetes care, actually started as a failed product — but key changes made it the ...

Abbott's Freestyle Libre 2 and 3 are the first CGMs to receive FDA clearance for use during imaging tests like X-rays, CT ...

The US Food and Drug Administration has okayed removal of the contraindication for use during CT and MRI under certain ...

We are excited to work with Abbott to empower healthcare providers and people living with diabetes to see data from their ...

We are excited to work with Abbott to empower healthcare providers and people living with diabetes to see data from their FreeStyle Libre sensors on Tidepool and Tidepool+,” said Brandon Arbiter ...

Adding to this cascade of innovation in the U.S., we are on track to launch Omnipod 5 integrated with Abbott's FreeStyle Libre 2 Plus sensor by the end of the year. We are excited to provide ...

FreeStyle Libre 2 sensors will be phased out in the UK by the end of August 2025, meaning that people living with diabetes who use the sensors will need to transition to using FreeStyle Libre 2 Plus ...

Abbott's FreeStyle Libre 2 and 3 continuous glucose monitors no longer need to be removed for imaging tests. CGM readings during an MRI may be affected for up to an hour after the procedure. While ...